The United States Food and Drug Administration (USFDA) has concluded inspection at Jubilant Pharmova’s Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud, India on December 13, 2022. The US FDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with US FDA for next steps.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
